Biotech Values

[turtlepower]

DEPO and Solvay - Well the reaction I had was the same reaction the CEO of DEPO had when an analyst asked the same question you did in the Q&A session after the trial results were presented, which is surprise given that the results were positive. Have a listen. It happens right at the beginning of the Q & A.

http://investor.depomedinc.com/phoenix.zhtml?c=97276&p=irol-EventDetails&EventId=2474151&WebCastId=918107&StreamId=1374809

I guess there's a risk for any biotech company when it partners with someone that the partner will void the contract. That risk decreases substantially when the program for the partnership is going well. I think given the current marketcap of DEPO, the amount of cash it has, the rest of its pipeline and the fact that it has two marketed products, I'm not too concerned about that risk even though the indication is not that novel .